Efficacy of trilostane for the treatment of equine Cushing's syndrome

McGowan, C. M. and Neiger, R. (2003) Efficacy of trilostane for the treatment of equine Cushing's syndrome. Equine Veterinary Journal, 35 4: 414-418. doi:10.2746/042516403776014271


Author McGowan, C. M.
Neiger, R.
Title Efficacy of trilostane for the treatment of equine Cushing's syndrome
Journal name Equine Veterinary Journal   Check publisher's open access policy
ISSN 0425-1644
2042-3306
Publication date 2003-01-01
Sub-type Article (original research)
DOI 10.2746/042516403776014271
Open Access Status Not yet assessed
Volume 35
Issue 4
Start page 414
End page 418
Total pages 5
Place of publication Newmarket, UK
Publisher Equine Veterinary Journal
Language eng
Subject 0707 Veterinary Sciences
Formatted abstract
Reasons for performing study: Trilostane, a competitive 3-beta hydroxysteroid dehydrogenase inhibitor, has been used successfully to control clinical signs and cortisol excess in canine pituitary dependent hyperadrenocorticism

Objectives: Trilostane was evaluated for its efficacy in resolving clinical and clinicopathological abnormalities of equine Cushing's syndrome (ECS) and to assess its safety.

Methods: Twenty horses (mean age 21 years) diagnosed with ECS were followed for 1 or 2 years. Affected horses received 0.4–1 mg/kg (mean 0.5 mg/kg) trilostane once daily.

Results: Clinical signs assessed over 1 or 2 years, showed a reduction in lethargy in all horses post treatment. Polyuria and/or polydipsia, present in 11 horses, was reduced in all after treatment. Recurrent or chronic laminitis, present in 16 horses, improved in 13/16 (81%) of cases. There were no side effects reported. Combined dexamethasone suppression and thyrotropin releasing hormone (TRH) stimulation tests were significantly different before and 30 days following therapy. There was a significant reduction (P = 0.01) of cortisol following TRH administration before (160 ± 53.0 nmol/l) and after (130 ± 46.1 nmol/l) trilostane.

Conclusions: Trilostane caused improvement in clinical signs in horses, without side effects, and a corresponding decrease in cortisol response to TRH administration.

Potential relevance: Trilostane may be a useful therapy for the treatment of ECS. Further work comparing the effects of trilostane and pergolide is warranted.
Keyword horse
trilostane
hyperadrenocorticism
cortisol
laminitis
pony
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Veterinary Science Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 34 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 48 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 06 Apr 2006, 23:14:07 EST